Winnow Wealth’s Alnylam Pharmaceuticals ALNY Stock Holding History

Winnow Wealth’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-4	Closed	-$1.59K	–	146
2025 Q4	$1.59K	Sell	4 -3	-43%	-$1.33K	﹤0.01%	381
2025 Q3	$3.19K	Buy	+7	New	+$2.85K	﹤0.01%	300
2025 Q2	–	Sell	-4	Closed	-$843	–	191
2025 Q1	$843	Buy	4 +1	+33%	+$257	﹤0.01%	409
2024 Q4	$491	Buy	+3	New	+$789	﹤0.01%	435

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Winnow Wealth's ALNY Position: Q1 2026 in Review

Winnow Wealth sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 4 shares — an estimated $1.59K sold.

Winnow Wealth first reported a position in ALNY in Q4 2024 and held it in 4 quarters. The position peaked at $3.19K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Winnow Wealth reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Winnow Wealth sold 4 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.59K.
Winnow Wealth first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 4 quarters.
Winnow Wealth's Alnylam Pharmaceuticals position peaked at $3.19K in Q3 2025.
793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Winnow Wealth's 13F filing for Q1 2026, filed 19 May 2026.